BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(13): 3777-3785 [PMID: 25852263 DOI: 10.3748/wjg.v21.i13.3777] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 68] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Ali ES, Petrovsky N. Calcium Signaling As a Therapeutic Target for Liver Steatosis. Trends Endocrinol Metab 2019;30:270-81. [PMID: 30850262 DOI: 10.1016/j.tem.2019.02.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
2 Castillo-Leon E, Cioffi CE, Vos MB. Perspectives on youth-onset nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00184. [PMID: 33102800 DOI: 10.1002/edm2.184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
3 Zheng J, Chen S, Cai Y, Lin S, Ke S, Liu L. Insufficient nocturnal sleep was associated with a higher risk of fibrosis in patients with diabetes with metabolic associated fatty liver disease. Ther Adv Endocrinol Metab 2020;11:2042018820947550. [PMID: 32973993 DOI: 10.1177/2042018820947550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Silva Figueiredo P, Inada AC, Ribeiro Fernandes M, Granja Arakaki D, Freitas KC, Avellaneda Guimarães RC, Aragão do Nascimento V, Aiko Hiane P. An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. Molecules 2018;23:E877. [PMID: 29641459 DOI: 10.3390/molecules23040877] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
5 Brol MJ, Rösch F, Schierwagen R, Magdaleno F, Uschner FE, Manekeller S, Queck A, Schwarzkopf K, Odenthal M, Drebber U, Thiele M, Lingohr P, Plamper A, Kristiansen G, Lotersztajn S, Krag A, Klein S, Rheinwalt KP, Trebicka J. Combination of CCl 4 with alcoholic and metabolic injuries mimics human liver fibrosis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2019;317:G182-94. [DOI: 10.1152/ajpgi.00361.2018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
6 Zhang DD, Zhang JG, Wu X, Liu Y, Gu SY, Zhu GH, Wang YZ, Liu GL, Li XY. Nuciferine downregulates Per-Arnt-Sim kinase expression during its alleviation of lipogenesis and inflammation on oleic acid-induced hepatic steatosis in HepG2 cells. Front Pharmacol 2015;6:238. [PMID: 26539118 DOI: 10.3389/fphar.2015.00238] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
7 Abraham JA, Golubnitschaja O. Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon? Per Med 2016;13:455-67. [PMID: 29767598 DOI: 10.2217/pme-2016-0013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Long JK, Dai W, Zheng YW, Zhao SP. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med 2019;25:26. [PMID: 31195981 DOI: 10.1186/s10020-019-0085-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
9 Kennedy-Martin T, Bae JP, Paczkowski R, Freeman E. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review. J Patient Rep Outcomes 2017;2:28. [PMID: 29984351 DOI: 10.1186/s41687-018-0052-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
10 Zhang CH, Zhou BG, Sheng JQ, Chen Y, Cao YQ, Chen C. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacol Res 2020;159:104984. [PMID: 32502637 DOI: 10.1016/j.phrs.2020.104984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Zhang Z, Zhou H, Guan M, Zhou X, Liang X, Lv Y, Bai L, Zhang J, Gong P, Liu T, Yi H, Wang J, Zhang L. Lactobacillus casei YRL577 combined with plant extracts reduce markers of non-alcoholic fatty liver disease in mice. Br J Nutr 2021;125:1081-91. [PMID: 32718364 DOI: 10.1017/S0007114520003013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lee MR, Yang HJ, Park KI, Ma JY. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice. Phytomedicine 2019;55:14-22. [PMID: 30668424 DOI: 10.1016/j.phymed.2018.07.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
13 Jung C, Lee B, Choi D, Jung S, Kim B, Kim C, Kang S, Mok J. Association of grade of non-alcoholic fatty liver disease and glycated albumin to glycated hemoglobin ratio in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2017;125:53-61. [DOI: 10.1016/j.diabres.2016.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Belloni L, Di Cocco S, Guerrieri F, Nunn ADG, Piconese S, Salerno D, Testoni B, Pulito C, Mori F, Pallocca M, Sacconi A, Vivoli E, Marra F, Strano S, Blandino G, Levrero M, Pediconi N. Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. Sci Rep 2018;8:13638. [PMID: 30206377 DOI: 10.1038/s41598-018-31835-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Kim K, Bae GD, Lee M, Park EY, Baek DJ, Kim CY, Jun HS, Oh YS. Allomyrina dichotoma Larva Extract Ameliorates the Hepatic Insulin Resistance of High-Fat Diet-Induced Diabetic Mice. Nutrients 2019;11:E1522. [PMID: 31277481 DOI: 10.3390/nu11071522] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
16 Ou-Yang Q, Xuan CX, Wang X, Luo HQ, Liu JE, Wang LL, Li TT, Chen YP, Liu J. 3-Acetyl-oleanolic acid ameliorates non-alcoholic fatty liver disease in high fat diet-treated rats by activating AMPK-related pathways. Acta Pharmacol Sin. 2018;39:1284-1293. [PMID: 29345253 DOI: 10.1038/aps.2017.142] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
17 冯梦君, 谢佳楠, 张怡歆, 谭周进, 唐标. 降脂理肝汤对非酒精性脂肪肝大鼠肝组织病理的影响. 世界华人消化杂志 2015; 23(16): 2532-2538 [DOI: 10.11569/wcjd.v23.i16.2532] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Biondo LA, Teixeira AAS, de O. S. Ferreira KC, Neto JCR. Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. CPD 2020;26:932-45. [DOI: 10.2174/1381612826666200122124116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Kim YJ, Park SY, Lee JH. Berteroin ameliorates lipid accumulation through AMPK-mediated regulation of hepatic lipid metabolism and inhibition of adipocyte differentiation. Life Sci 2021;282:119668. [PMID: 34087283 DOI: 10.1016/j.lfs.2021.119668] [Reference Citation Analysis]
20 Engin A. Non-Alcoholic Fatty Liver Disease. In: Engin AB, Engin A, editors. Obesity and Lipotoxicity. Cham: Springer International Publishing; 2017. pp. 443-67. [DOI: 10.1007/978-3-319-48382-5_19] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 21.3] [Reference Citation Analysis]
21 Safadi R, Braun M, Francis A, Milgrom Y, Massarwa M, Hakimian D, Hazou W, Issachar A, Harpaz Z, Farbstein M, Itzhak I, Lev-Cohain N, Bareket-Samish A, Silverman MH, Fishman P. Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. Aliment Pharmacol Ther 2021;54:1405-15. [PMID: 34671996 DOI: 10.1111/apt.16664] [Reference Citation Analysis]
22 Shi Y, Zhang W, Cheng Y, Liu C, Chen S. Bromide alleviates fatty acid-induced lipid accumulation in mouse primary hepatocytes through the activation of PPARα signals. J Cell Mol Med 2019;23:4464-74. [PMID: 31033195 DOI: 10.1111/jcmm.14347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Li Y, Zhang T, Liu Q, Zhang J, Li R, Pu S, Wu T, Ma L, He J. Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis. Int J Nanomedicine 2019;14:3943-53. [PMID: 31239664 DOI: 10.2147/IJN.S202821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Al-Muzafar HM, Amin KA. Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin. Exp Ther Med 2018;16:2938-48. [PMID: 30214514 DOI: 10.3892/etm.2018.6563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Hong W, Li S, Wu L, He B, Jiang J, Chen Z. Prediction of VEGF-C as a Key Target of Pure Total Flavonoids From Citrus Against NAFLD in Mice via Network Pharmacology. Front Pharmacol 2019;10:582. [PMID: 31214028 DOI: 10.3389/fphar.2019.00582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Pfohl M, DaSilva NA, Marques E, Agudelo J, Liu C, Goedken M, Slitt AL, Seeram NP, Ma H. Hepatoprotective and anti-inflammatory effects of a standardized pomegranate (Punica granatum) fruit extract in high fat diet-induced obese C57BL/6 mice. Int J Food Sci Nutr 2021;72:499-510. [PMID: 33203257 DOI: 10.1080/09637486.2020.1849041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Muraki Y, Makita Y, Yamasaki M, Amano Y, Matsuo T. Elevation of liver endoplasmic reticulum stress in a modified choline-deficient l -amino acid-defined diet-fed non-alcoholic steatohepatitis mouse model. Biochemical and Biophysical Research Communications 2017;486:632-8. [DOI: 10.1016/j.bbrc.2017.03.072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Whitsett M, VanWagner LB. Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review. World J Hepatol 2015; 7(16): 2041-2052 [PMID: 26261693 DOI: 10.4254/wjh.v7.i16.2041] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
29 Yadati T, Houben T, Bitorina A, Oligschlaeger Y, Gijbels MJ, Mohren R, Lütjohann D, Khurana P, Goyal S, Kulkarni A, Theys J, Cillero-Pastor B, Shiri-Sverdlov R. Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice. Front Immunol 2021;12:675535. [PMID: 34335574 DOI: 10.3389/fimmu.2021.675535] [Reference Citation Analysis]
30 Fishman P, Cohen S, Itzhak I, Amer J, Salhab A, Barer F, Safadi R. The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice. Int J Mol Med 2019;44:2256-64. [PMID: 31638172 DOI: 10.3892/ijmm.2019.4364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
31 Sharma L, Gupta D, Abdullah ST. Thioacetamide potentiates high cholesterol and high fat diet induced steato-hepatitic changes in livers of C57BL/6J mice: A novel eight weeks model of fibrosing NASH. Toxicology Letters 2019;304:21-9. [DOI: 10.1016/j.toxlet.2019.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
32 Deng Y, Pan M, Nie H, Zheng C, Tang K, Zhang Y, Yang Q. Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats. Molecules 2019;24:E3943. [PMID: 31683679 DOI: 10.3390/molecules24213943] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
33 Venkatasubramanian A, Thiyagaraj A, Subbiah V, Solairaja S, Arumugam S, Ramalingam S, Venkatabalasubramanian S. Ameliorative role of ellagic acid against acute liver steatosis in adult zebrafish experimental model. Comp Biochem Physiol C Toxicol Pharmacol 2021;247:109061. [PMID: 33901636 DOI: 10.1016/j.cbpc.2021.109061] [Reference Citation Analysis]
34 Al-Baiaty FDR, Ismail A, Abdul Latiff Z, Muhammad Nawawi KN, Raja Ali RA, Mokhtar NM. Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents. Front Pediatr 2021;9:667247. [PMID: 34307250 DOI: 10.3389/fped.2021.667247] [Reference Citation Analysis]
35 Lin T, Li L, Liang C, Peng L. Network Pharmacology-Based Investigation of the Therapeutic Mechanisms of Action of Danning Tablets in Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2021;2021:3495360. [PMID: 33995543 DOI: 10.1155/2021/3495360] [Reference Citation Analysis]
36 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
37 Ganesh S, Rustgi VK. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:351-64. [PMID: 27063274 DOI: 10.1016/j.cld.2015.10.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
38 Jia WQ, Zhou TC, Dai JW, Liu ZN, Zhang YF, Zang DD, Lv XW. CD73 regulates hepatic stellate cells activation and proliferation through Wnt/β-catenin signaling pathway. Eur J Pharmacol 2021;890:173667. [PMID: 33121948 DOI: 10.1016/j.ejphar.2020.173667] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Borém LMA, Neto JFR, Brandi IV, Lelis DF, Santos SHS. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res 2018;41:394-405. [PMID: 29636553 DOI: 10.1038/s41440-018-0040-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
40 Murotomi K, Arai S, Uchida S, Endo S, Mitsuzumi H, Tabei Y, Yoshida Y, Nakajima Y. Involvement of splenic iron accumulation in the development of nonalcoholic steatohepatitis in Tsumura Suzuki Obese Diabetes mice. Sci Rep 2016;6:22476. [PMID: 26932748 DOI: 10.1038/srep22476] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
41 Martínez Soriano B, Güemes A, Pola G, Gonzalo A, Palacios Gasós P, Navarro AC, Martínez-Beamonte R, Osada J, García JJ. Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model. Can J Gastroenterol Hepatol 2020;2020:7315253. [PMID: 32566547 DOI: 10.1155/2020/7315253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Jin ES, Sherry AD, Malloy CR. An Oral Load of [13C3]Glycerol and Blood NMR Analysis Detect Fatty Acid Esterification, Pentose Phosphate Pathway, and Glycerol Metabolism through the Tricarboxylic Acid Cycle in Human Liver. J Biol Chem 2016;291:19031-41. [PMID: 27432878 DOI: 10.1074/jbc.M116.742262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
43 Wang JZ, Cao HX, Chen JN, Pan Q. PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease. World J Clin Cases 2018; 6(8): 167-175 [PMID: 30148144 DOI: 10.12998/wjcc.v6.i8.167] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
44 Tekbas A, Huebner J, Settmacher U, Dahmen U. Plants and Surgery: The Protective Effects of Thymoquinone on Hepatic Injury-A Systematic Review of In Vivo Studies. Int J Mol Sci 2018;19:E1085. [PMID: 29621129 DOI: 10.3390/ijms19041085] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
45 Zhou J, Ho CT, Long P, Meng Q, Zhang L, Wan X. Preventive Efficiency of Green Tea and Its Components on Nonalcoholic Fatty Liver Disease. J Agric Food Chem 2019;67:5306-17. [PMID: 30892882 DOI: 10.1021/acs.jafc.8b05032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
46 Sun X, Zhang Y, Xie M. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease. Acta Pharmaceutica 2017;67:1-13. [DOI: 10.1515/acph-2017-0007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
47 Ashraf NU, Sheikh TA. Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radic Res. 2015;49:1405-1418. [PMID: 26223319 DOI: 10.3109/10715762.2015.1078461] [Cited by in Crossref: 145] [Cited by in F6Publishing: 137] [Article Influence: 24.2] [Reference Citation Analysis]
48 Zhu M, Li M, Zhou W, Yang Y, Li F, Zhang L, Ji G. Qianggan extract improved nonalcoholic steatohepatitis by modulating lncRNA/circRNA immune ceRNA networks. BMC Complement Altern Med 2019;19:156. [PMID: 31269941 DOI: 10.1186/s12906-019-2577-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
49 Liu Y, Liao L, Chen Y, Han F. Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells. Mol Med Rep 2019;19:4673-84. [PMID: 30957185 DOI: 10.3892/mmr.2019.10139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Zhang R, Cheng K, Xu S, Li S, Zhou Y, Zhou S, Kong R, Li L, Li J, Feng J, Wu L, Liu T, Xia Y, Lu J, Guo C, Zhou Y. Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Gastroenterol Res Pract 2017;2017:8491742. [PMID: 28133479 DOI: 10.1155/2017/8491742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Pandey A, Raj P, Goru SK, Kadakol A, Malek V, Sharma N, Gaikwad AB. Esculetin ameliorates hepatic fibrosis in high fat diet induced non-alcoholic fatty liver disease by regulation of FoxO1 mediated pathway. Pharmacol Rep 2017;69:666-72. [PMID: 28527877 DOI: 10.1016/j.pharep.2017.02.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
52 Berk PD, Verna EC. Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance. Clin Liver Dis. 2016;20:245-262. [PMID: 27063267 DOI: 10.1016/j.cld.2015.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
53 Ma P, Sun C, Li W, Deng W, Adu-Frimpong M, Yu J, Xu X. Extraction and structural analysis of Angelica sinensis polysaccharide with low molecular weight and its lipid-lowering effect on nonalcoholic fatty liver disease. Food Sci Nutr 2020;8:3212-24. [PMID: 32724586 DOI: 10.1002/fsn3.1581] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
54 Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E, Luzza F. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients 2017;9:E870. [PMID: 28805669 DOI: 10.3390/nu9080870] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
55 Wollman A, Daniel T, Rosenzweig T. Sarcopoterium spinosum Inhibited the Development of Non-Alcoholic Steatosis and Steatohepatitis in Mice. Nutrients 2019;11:E3044. [PMID: 31847157 DOI: 10.3390/nu11123044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Guifang T, Xiangwen G, Qinhe Y, Yuanyuan L, Guanlong W, Yinji L, Yupei Z, Haizhen Y, Chunmei L, Jinwen Z. Effects of extracts from soothing-liver and invigorating-spleen formulas on the injury induced by oxidative stress in the hepatocytes of rats with non-alcoholic fatty liver disease induced by high-fat diet. Journal of Traditional Chinese Medicine 2018;38:535-47. [DOI: 10.1016/s0254-6272(18)30885-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Parafati M, Lascala A, La Russa D, Mignogna C, Trimboli F, Morittu VM, Riillo C, Macirella R, Mollace V, Brunelli E, Janda E. Bergamot Polyphenols Boost Therapeutic Effects of the Diet on Non-Alcoholic Steatohepatitis (NASH) Induced by "Junk Food": Evidence for Anti-Inflammatory Activity. Nutrients 2018;10:E1604. [PMID: 30388763 DOI: 10.3390/nu10111604] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
58 Yu Q, Liu Y, Wu Y, Chen Y. Dihydrocurcumin ameliorates the lipid accumulation, oxidative stress and insulin resistance in oleic acid-induced L02 and HepG2 cells. Biomedicine & Pharmacotherapy 2018;103:1327-36. [DOI: 10.1016/j.biopha.2018.04.143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
59 Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther 2015;9:4835-45. [PMID: 26316717 DOI: 10.2147/DDDT.S64877] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
60 Xie C, Chen Z, Zhang C, Xu X, Jin J, Zhan W, Han T, Wang J. Dihydromyricetin ameliorates oleic acid-induced lipid accumulation in L02 and HepG2 cells by inhibiting lipogenesis and oxidative stress. Life Sci. 2016;157:131-139. [PMID: 27265384 DOI: 10.1016/j.lfs.2016.06.001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
61 Choi S, Jung HJ, Kim MW, Kang JH, Shin D, Jang YS, Yoon YS, Oh SH. A novel STAT3 inhibitor, STX-0119, attenuates liver fibrosis by inactivating hepatic stellate cells in mice. Biochem Biophys Res Commun. 2019;513:49-55. [PMID: 30935693 DOI: 10.1016/j.bbrc.2019.03.156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
62 Liu J, Yuan Y, Gong X, Zhang L, Zhou Q, Wu S, Zhang X, Hu J, Kuang G, Yin X, Wan J, Yuan Y. Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice. Int Immunopharmacol 2020;80:106208. [PMID: 31955065 DOI: 10.1016/j.intimp.2020.106208] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
63 唐标, 冯梦君, 谢佳楠, 张怡歆, 谭周进, 邓冰湘. 降脂理肝汤对非酒精性脂肪肝大鼠生化指标的影响. 世界华人消化杂志 2015; 23(18): 2942-2946 [DOI: 10.11569/wcjd.v23.i18.2942] [Reference Citation Analysis]
64 Handa P, Vemulakonda A, Kowdley KV, Uribe M, Méndez-Sánchez N. Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis? World J Gastroenterol 2016; 22(31): 6965-6971 [PMID: 27610009 DOI: 10.3748/wjg.v22.i31.6965] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
65 Huang P, Huang FZ, Liu HZ, Zhang TY, Yang MS, Sun CZ. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism 2019;94:1-8. [PMID: 30711569 DOI: 10.1016/j.metabol.2019.01.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 16.5] [Reference Citation Analysis]
66 Gao J, Song J, Du M, Mao X. Bovine α-lactalbumin hydrolysates (α-LAH) attenuate high-fat diet induced nonalcoholic fatty liver disease by modulating hepatic lipid metabolism in C57BL/6J mice. Journal of Functional Foods 2019;54:254-62. [DOI: 10.1016/j.jff.2019.01.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
67 Cheng B, Zhou AZ, Ge W, Yao XM, Wang J. Mechanism of Huo-Xue-Qu-Yu Formula in Treating Nonalcoholic Hepatic Steatosis by Regulating Lipid Metabolism and Oxidative Stress in Rats. Evid Based Complement Alternat Med 2021;2021:6026319. [PMID: 34007294 DOI: 10.1155/2021/6026319] [Reference Citation Analysis]
68 Khalaf HM, Ibrahim MA, Amin EF, Abdel-Tawab Ibrahim S, Abdel-Wahab S, Fouad YM. Allopurinol potentiates the hepatoprotective effect of metformin and vitamin E in fructose-induced fatty liver in rats. Clin Exp Hepatol 2019;5:65-74. [PMID: 30915409 DOI: 10.5114/ceh.2019.83159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]